<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00767494</url>
  </required_header>
  <id_info>
    <org_study_id>C-07-63</org_study_id>
    <nct_id>NCT00767494</nct_id>
  </id_info>
  <brief_title>Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the IOP lowering efficacy of Travoprost/Brinzolamide
      dosed daily in the morning or evening, vs TRAVATAN dosed once daily in the evening, and vs.
      AZOPT dosed BID in patients with open-angle glaucoma or ocular hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Project Cancelled
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean IOP</measure>
    <time_frame>9, 11, and 16:00 time points at Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean diurnal IOP at Week 12</measure>
    <time_frame>results pooled across 9,11, and 16:00 time points</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Travoprost/Brinzolamide AM, Vehicle PM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Travoprost/Brinzolamide PM, Vehicle AM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AZOPT AM and PM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TRAVATAN PM, Vehicle AM</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost/Brinzolamide fixed combination</intervention_name>
    <description>Eye Drops, suspension once daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azopt</intervention_name>
    <description>Eye Drop Suspension, 1 drop BID</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travatan</intervention_name>
    <description>Eye Drop Solution, 1 drop BID</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 YOA or older

          -  Either gender or any race

          -  OAG or OHT

          -  Currently on stable (at least 4 weeks) IOP lowering medication

          -  IOP at screening visit â‰¥ 18mmHg in at least one eye

          -  Mean IOP in same eye (at both eligibility 1&amp;2 visits

          -  24 and 36 mmHg at 9AM

          -  21 and 36 mmHg at 11AM and 4PM

          -  Able to discontinue use of IOP lowering medication for a minimum wash out period of 5
             to 28 days prior to eligibility visit 1

        Exclusion Criteria:

        Related to disease condition being investigated (OAG or OHT) in either eye

          -  Severe central visual field loss

          -  Angle shaffer grade &lt; 2

          -  C/D ratio &gt;0.8(horizontal or vertical measurement)

        Related to ocular patient history or current ocular condition in either eye

          -  BSCVA worse than 55 ETDRS letters read (equivalent to approximately 20/80 Snellen or
             0.25 decimal)

          -  Ocular infection or inflammation or laser surgery within the last 3 months

          -  Intraocular surgery or trauma with the last 6 months

          -  Any abnormality preventing reliable applanation tonometry

          -  History or chronic, recurrently or current severe inflammatory disease

          -  History of or current clinically significant or progressive retinal disease

          -  History of or current ocular pathology(including severe dry eye) that would affect the
             conduct of the study

        Related to systemic or ocular medication in either eye

          -  Allergy/hypersensitivity to study medications

          -  Unable to discontinue glucocorticoid at least 4 weeks prior to the study or unable to
             remain off these medications during the study period

          -  Use of oral CAIs during the study

          -  Recent use (&lt;4 weeks prior to the study) of Aspirin (&gt;1 gram)

          -  Less than 30 days stable dosing regimen of medications used on a chronic basis that
             may affect IOP

          -  Therapy with another investigational agent within 30 days prior to the Screening Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2008</study_first_submitted>
  <study_first_submitted_qc>October 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2008</study_first_posted>
  <last_update_submitted>September 18, 2012</last_update_submitted>
  <last_update_submitted_qc>September 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OAG</keyword>
  <keyword>OH</keyword>
  <keyword>Open-angle glaucoma or ocular hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Travoprost</mesh_term>
    <mesh_term>Brinzolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

